Investor Presentaiton

Live attenuated vaccine (SP0125) Phase 1/2 design Days 1 DT 56 84 > Safety I I RSVt - Low dose n=61 Toddlers 6-18 mo RSVt High dose n=57 32 Vaccines Investor Event Placebo n=61 sanofi Adverse events following vaccination > Immunogenicity Neutralizing antibody responses > Vaccine response rate Composite endpoint factoring immunogenicity and vaccine virus replication

View entire presentation